Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
To assess CDK4/6i toxicity and effect on PFS in the Egyptian population
Toxicity, Drug|Progression, Disease
DRUG: CDK4/6 Inhibitor
Adverse effect, assess the toxicity profile, 2 years
PFS, PFS in patient receiving CDK4/6i in Egypt, 2 years
To assess CDK4/6i toxicity and effect on PFS in the Egyptian population